

Antibody Drug Conjugates Contract Manufacturing Market Size, Share & Trends Analysis Report By Linker (Cleavable, Non-cleavable), By Condition (Myeloma, Lymphoma, Breast Cancer), By Region, And Segment Forecasts, 2023 - 2030

<https://marketpublishers.com/r/AC71B84977FDEN.html>

Date: November 2022

Pages: 130

Price: US\$ 5,950.00 (Single User License)

ID: AC71B84977FDEN

Abstracts

This report can be delivered to the clients within 2 Business Days

Antibody Drug Conjugates Contract Manufacturing Market Growth & Trends

The global antibody drug conjugates contract manufacturing market size is expected to reach USD 25.79 billion by 2030, registering a CAGR of 12.9% over the forecast period, according to a new report by Grand View Research, Inc. The factors driving the industry growth include the complex nature of antibody drug conjugates (ADCs) contributing to the demand for contract manufacturing, the increasing number of research on antibody therapies, and the rise in cancer incidence. During the pandemic, the clinical trials for cancer were stopped for a short period. However, owing to the severity of the disease, the trials were started again. As per the IQVIA Oncology Trends Report 2022, the number of clinical trials for cancer is growing.

The IQVIA report states that there was a 56% increase in oncology clinical trials between 2016 and 2021. This number of clinical studies is expected to rise even further owing to the growing prevalence of cancer worldwide. This is expected to support the ADC development and manufacturing activities, thus supporting industry growth post-pandemic. Antibody drug conjugates have high efficiency in treating cancer as it only targets the cancerous cells and does not affect the healthy cells of the body. As a result, several biopharmaceutical companies have received significant funding for ADC-related research.

For instance, in October 2022, Mablink Bioscience, raised USD 31 million from Series A funding to build its antibody drug conjugate pipeline. Thus, heavy investments in the R&D of ADCs are expected to improve their availability in the coming years and thus support the demand for ADC contract manufacturing. In September 2021, the U.S. FDA provided accelerated approval for ADC tisotumab vedotin-tftv for treating adult patients with recurrent or metastatic cervical cancer with disease progression or after chemotherapy. Such approvals, in the coming years, are expected to boost the demand for contract manufacturing services for ADC.

Antibody Drug Conjugates Contract Manufacturing Market Report Highlights

By condition, the lymphoma segment is expected to grow at the fastest CAGR over the forecast period

A significant number of ADCs under development for lymphoma and collaborations for ADC-related research for lymphoma are supporting the growth of the segment over the forecast period

Based on the linker, the cleavable linker segment accounted for the maximum share of the overall revenue in 2022

Extensive use of cleavable linker technology in ADC and a greater number of cleavable linker-based products in the pipeline are the factors responsible for the segment growth

Asia Pacific dominated the global industry in 2022 and accounted for the maximum revenue share

This is due to the robust improvements in R&D activities in emerging markets and low-cost manufacturing in the region as compared to that of developed countries

Contents

CHAPTER 1. METHODOLOGY AND SCOPE

- 1.1. Market Segmentation & Scope
 - 1.1.1. Condition
 - 1.1.2. Linker
 - 1.1.3. Regional scope
 - 1.1.4. Estimates and forecast timeline
- 1.2. Research Methodology
- 1.3. Information Procurement
 - 1.3.1. Purchased database
 - 1.3.2. GVR's internal database
 - 1.3.3. Secondary sources
 - 1.3.4. Primary research
 - 1.3.5. Details of primary research
- 1.4. Information or Data Analysis
 - 1.4.1. Data analysis models
- 1.5. Market Formulation & Validation
- 1.6. Model Details
 - 1.6.1. Commodity flow analysis (Model 1)
 - 1.6.1.1. Approach 1: Commodity flow approach
- 1.7. List of Secondary Sources
- 1.8. List of Primary Sources
- 1.9. Objectives
 - 1.9.1. Objective
 - 1.9.2. Objective

CHAPTER 2. EXECUTIVE SUMMARY

- 2.1. Market Outlook

CHAPTER 3. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET VARIABLES, TRENDS & SCOPE

- 3.1. Market Lineage Outlook
 - 3.1.1. Parent market outlook
 - 3.1.2. Related/ancillary market outlook
- 3.2. Market Dynamics

- 3.2.1. Market driver analysis
 - 3.2.1.1. Rising incidence of cancer
 - 3.2.1.2. High cost of manufacturing ADC and challenges associated with manufacturing contributing to the demand for contract manufacturing
 - 3.2.1.3. Increasing R&D activities on ADCs
- 3.2.2. Market restraint analysis
 - 3.2.2.1. Quality issues while outsourcing
 - 3.2.2.2. Limited outsourcing opted by big biopharma Companies
- 3.3. Antibody Drug Conjugates Contract Manufacturing Market Analysis Tools
 - 3.3.1. Porter's Five Forces Analysis
 - 3.3.2. PESTLE Analysis
 - 3.3.3. Major Deals & Strategic Alliances Analysis
 - 3.3.3.1. Mergers and acquisition
 - 3.3.3.2. Expansions
 - 3.3.3.3. Agreements and collaborations
 - 3.3.3.4. Product and service launches
- 3.4. Covid-19 Impact and Reformation Strategy

CHAPTER 4. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET: CONDITION ESTIMATES & TREND ANALYSIS

- 4.1. Definitions and Scope
- 4.2. Antibody Drug Conjugates Contract Manufacturing Market Share, 2022 & 2030
- 4.3. Myeloma
 - 4.3.1. Myeloma market estimates and forecast 2018 to 2030 (USD Million)
- 4.4. Lymphoma
 - 4.4.1. Lymphoma market estimates and forecast 2018 to 2030 (USD Million)
- 4.5. Breast Cancer
 - 4.5.1. Breast Cancer market estimates and forecast 2018 to 2030 (USD Million)
- 4.6. Others
 - 4.6.1. Others market estimates and forecast 2018 to 2030 (USD Million)

CHAPTER 5. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET: LINKER ESTIMATES & TREND ANALYSIS

- 5.1. Definitions and Scope
- 5.2. Antibody Drug Conjugates Contract Manufacturing Market Share, 2022 & 2030
- 5.3. Cleavable linker
 - 5.3.1. Cleavable linker market estimates and forecast 2018 to 2030 (USD Million)

5.4. Non-cleavable linker

5.4.1. Non-cleavable linker market estimates and forecast 2018 to 2030 (USD Million)

CHAPTER 6. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET: REGIONAL ESTIMATES & TREND ANALYSIS

6.1. Regional market share analysis, 2022 & 2030

6.2. North America

6.2.1. U.S.

6.2.1.1. U.S. market estimates and forecast, 2018 - 2030

6.2.2. Canada

6.2.2.1. Canada market estimates and forecast, 2018 - 2030

6.3. Europe

6.3.1. U.K.

6.3.1.1. U.K. market estimates and forecast, 2018 - 2030

6.3.2. Germany

6.3.2.1. Germany market estimates and forecast, 2018 - 2030

6.3.3. France

6.3.3.1. France market estimates and forecast, 2018 - 2030

6.3.4. Italy

6.3.4.1. Italy market estimates and forecast, 2018 - 2030

6.3.5. Spain

6.3.5.1. Spain market estimates and forecast, 2018 - 2030

6.3.6. Denmark

6.3.6.1. Denmark market estimates and forecast, 2018 - 2030

6.3.7. Sweden

6.3.7.1. Sweden market estimates and forecast, 2018 - 2030

6.3.8. Norway

6.3.8.1. Norway market estimates and forecast, 2018 - 2030

6.4. Asia Pacific

6.4.1. Japan

6.4.1.1. Japan market estimates and forecast, 2018 - 2030

6.4.2. China

6.4.2.1. China market estimates and forecast, 2018 - 2030

6.4.3. India

6.4.3.1. India market estimates and forecast, 2018 - 2030

6.4.4. Australia

6.4.4.1. Australia market estimates and forecast, 2018 - 2030

6.4.5. Thailand

- 6.4.5.1. Thailand market estimates and forecast, 2018 - 2030
- 6.4.6. South Korea
 - 6.4.6.1. South Korea market estimates and forecast, 2018 - 2030
- 6.5. Latin America
 - 6.5.1. Brazil
 - 6.5.1.1. Brazil market estimates and forecast, 2018 - 2030
 - 6.5.2. Mexico
 - 6.5.2.1. Mexico market estimates and forecast, 2018 - 2030
 - 6.5.3. Argentina
 - 6.5.3.1. Argentina market estimates and forecast, 2018 - 2030
- 6.6. MEA
 - 6.6.1. South Africa
 - 6.6.1.1. South Africa market estimates and forecast, 2018 - 2030
 - 6.6.2. Saudi Arabia
 - 6.6.2.1. Saudi Arabia market estimates and forecast, 2018 - 2030
 - 6.6.3. UAE
 - 6.6.3.1. UAE market estimates and forecast, 2018 - 2030
 - 6.6.4. Kuwait
 - 6.6.4.1. Kuwait market estimates and forecast, 2018 - 2030

CHAPTER 7. COMPETITIVE ANALYSIS

- 7.1. Recent Developments & Impact Analysis, By Key Market Participant
- 7.2. Company/Competition Categorization (Key Innovators, Market Leaders, Emerging Players)
- 7.3. Participant Categorization

CHAPTER 8. COMPETITIVE LANDSCAPE

- 8.1. Company Profiles
 - 8.1.1. Recipharm AB
 - 8.1.1.1. Company overview
 - 8.1.1.2. Financial performance
 - 8.1.1.3. Service benchmarking
 - 8.1.1.4. Strategic initiatives
 - 8.1.2. Samsung Biologics
 - 8.1.2.1. Company overview
 - 8.1.2.2. Financial performance
 - 8.1.2.3. Service benchmarking

- 8.1.2.4. Strategic initiatives
- 8.1.3. Lonza
 - 8.1.3.1. Company overview
 - 8.1.3.2. Financial performance
 - 8.1.3.3. Service benchmarking
 - 8.1.3.4. Strategic initiatives
- 8.1.4. Piramal Group (Piramal Pharma Solutions)
 - 8.1.4.1. Company overview
 - 8.1.4.2. Financial performance
 - 8.1.4.3. Service benchmarking
 - 8.1.4.4. Strategic initiatives
- 8.1.5. Sterling
 - 8.1.5.1. Company overview
 - 8.1.5.2. Financial performance
 - 8.1.5.3. Service benchmarking
 - 8.1.5.4. Strategic initiatives
- 8.1.6. Sartorius AG
 - 8.1.6.1. Company overview
 - 8.1.6.2. Financial performance
 - 8.1.6.3. Service benchmarking
 - 8.1.6.4. Strategic initiatives
- 8.1.7. Catalent, Inc
 - 8.1.7.1. Company overview
 - 8.1.7.2. Financial performance
 - 8.1.7.3. Service benchmarking
 - 8.1.7.4. Strategic initiatives
- 8.1.8. Wuxi Biologics
 - 8.1.8.1. Company overview
 - 8.1.8.2. Financial performance
 - 8.1.8.3. Service benchmarking
 - 8.1.8.4. Strategic initiatives
- 8.1.9. AbbVie, Inc. (AbbVie Contract Manufacturing)
 - 8.1.9.1. Company overview
 - 8.1.9.2. Financial performance
 - 8.1.9.3. Service benchmarking
 - 8.1.9.4. Strategic initiatives
- 8.1.10. Merck KGaA
 - 8.1.10.1. Company overview
 - 8.1.10.2. Financial performance

8.1.10.3. Service benchmarking

8.1.10.4. Strategic initiatives

List Of Tables

LIST OF TABLES

Table 1 List of secondary sources

Table 2 List of Abbreviations

List Of Figures

LIST OF FIGURES

- Fig 1 Market research process
- Fig. 2 Information procurement
- Fig. 3 Primary research pattern
- Fig. 4 Market research approaches
- Fig. 5 Value-chain-based sizing & forecasting
- Fig. 6 QFD modeling for market share assessment
- Fig. 7 Market formulation & validation
- Fig. 8 Commodity flow analysis
- Fig. 9 Volume Price Analysis
- Fig. 10 Antibody drug conjugates contract manufacturing market snapshot (2022)
- Fig. 11 Antibody drug conjugates contract manufacturing market segmentation
- Fig. 12 Market driver relevance analysis (Current & future impact)
- Fig. 13 Market restraint relevance analysis (Current & future impact)
- Fig. 14 Penetration & growth prospect mapping
- Fig. 15 Porter's five forces analysis
- Fig. 16 SWOT analysis, by factor (political & legal, economic and technological)
- Fig. 17 Antibody drug conjugates contract manufacturing market condition outlook:
Segment dashboard
- Fig. 18 Antibody drug conjugates contract manufacturing market: Condition movement
analysis
- Fig. 19 Myeloma market (USD Million)
- Fig. 20 Lymphoma market (USD Million)
- Fig. 21 Breast Cancer market (USD Million)
- Fig. 22 Others market (USD Million)
- Fig. 23 Antibody drug conjugates contract manufacturing market linker outlook:
Segment dashboard
- Fig. 24 Antibody drug conjugates contract manufacturing market: Linker movement
analysis
- Fig. 25 Cleavable Linker market (USD Million)
- Fig. 26 Non-Cleavable Linker market (USD Million)
- Fig. 27 Regional market: Key takeaways
- Fig. 28 Regional outlook, 2022 & 2030
- Fig. 29 North America market, 2018 - 2030 (USD Million)
- Fig. 30 U.S. market, 2018 - 2030 (USD Million)
- Fig. 31 Canada Market, , 2018 -2030 (USD Million)

- Fig. 32 Europe Market, , 2018 -2030 (USD Million)
- Fig. 33 U.K. Market, , 2018 -2030 (USD Million)
- Fig. 34 Germany Market, , 2018 -2030 (USD Million)
- Fig. 35 France Market, , 2018 -2030 (USD Million)
- Fig. 36 Italy Market, 2018 -2030 (USD Million)
- Fig. 37 SpainMarket, 2018 -2030 (USD Million)
- Fig. 38 Denmark Market, 2018 -2030 (USD Million)
- Fig. 39 SwedenMarket, 2018 -2030 (USD Million)
- Fig. 40 Norway Market, By Service, 2018 -2030 (USD Million)
- Fig. 41 Asia Pacific market, 2018 - 2030 (USD Million)
- Fig. 42 China market, 2018 - 2030 (USD Million)
- Fig. 43 India market, 2018 - 2030 (USD Million)
- Fig. 44 Japan market, 2018 - 2030 (USD Million)
- Fig. 45 Australia market, 2018 - 2030 (USD Million)
- Fig. 46 Thailand market, 2018 - 2030 (USD Million)
- Fig. 47 South Korea market, 2018 - 2030 (USD Million)
- Fig. 48 Latin America market, 2018 - 2030 (USD Million)
- Fig. 49 Brazil market, 2018 - 2030 (USD Million)
- Fig. 50 Mexico market, 2018 - 2030 (USD Million)
- Fig. 51 Argentina market, 2018 - 2030 (USD Million)
- Fig. 52 MEA market, 2018 - 2030 (USD Million)
- Fig. 53 South Africa market, 2018 - 2030 (USD Million)
- Fig. 54 Saudi Arabia market, 2018 - 2030 (USD Million)
- Fig. 55 UAE market, 2018 - 2030 (USD Million)
- Fig. 56 Kuwait market, 2018 - 2030 (USD Million)

I would like to order

Product name: Antibody Drug Conjugates Contract Manufacturing Market Size, Share & Trends Analysis Report By Linker (Cleavable, Non-cleavable), By Condition (Myeloma, Lymphoma, Breast Cancer), By Region, And Segment Forecasts, 2023 - 2030

Product link: <https://marketpublishers.com/r/AC71B84977FDEN.html>

Price: US\$ 5,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/AC71B84977FDEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970